Search results for " monoclonal" in Articles / App Notes
Article
Continuous Processing for the Production of Biopharmaceuticals
In recent years, there have been publications reporting development of a fully integrated end-to-end commercial continuous process for the manufacturing of recombinant monoclonal antibodies (5).
T…
Article
Optimizing Cation-Exchange Chromatography with High-Throughput Process Development for mAb Purification
By Anna Grönberg
An important area of focus for the biopharma industry is the elucidation and development of robust, efficient, and economic purification strategies for new monoclonal antibodies (…
Article
Quality by design for biotechnology products—part 1
Understanding the structure and functional attributes of therapeutic proteins, including monoclonal antibodies (MAbs), is key to developing the design space, because that understanding facilitates the…
Article
Modeling the Degradation of mAb Therapeutics
This is particularly true for monoclonal antibodies (mAbs), which account for most commercial biopharmaceuticals today. Both physical effects such as aggregation and chemical modifications (e.g., frag…
Article
Scaling Up Novel Therapies
Used almost exclusively for monoclonal antibodies (mAbs), platforms help shorten development times, particularly early in development, Ransohoff says. They also allow manufacturers to leverage perform…
Article
Recent Advances in the Use of Exoglycosidases to Improve Structural Profiling of N-glycans from Biologic Drugs
For example, the time needed to achieve enzymatic deglycosylation of monoclonal antibodies has been reduced by nearly two orders of magnitude. Certain products (e.g., Rapid PNGase F, New England Biola…
Article
Development and Future of Protein A Chromatography Technology: Q&A with Jonathan Royce, Business Leader Chromatography Resins, Cytiva
Cytiva stated in a recent press release that a new standard for monoclonal antibody purification is being set. Can you elaborate on that?
At Cytiva, we felt that with our knowledge and experience…
Article
Witnessing Major Growth in Next-Generation Antibodies
Challener
Next-generation antibodies are designed to be more specific and are often more potent than traditional monoclonal antibodies (mAbs). As a result, their commercial potential is significan…
Article
Analysis of Glycosylation in Biosimilars
The structures of protein drugs such as monoclonal antibodies are made more complex by post-translational modifications. The most notable of these is glycosylation, where carbohydrate residues are att…
Article
Platform Approach Speeds Process Development
By Harald Bradl, Jan Bechmann, Benedikt Greulich, Markus Michael Mueller, Patrick Schulz, Thomas Wucherpfennig
Commercial production of complex biopharmaceuticals such as recombinant monoclonal an…